key: cord-1033610-ruflp8ts
authors: Garvey, Mark I.; Casey, Anna L.; Wilkinson, Martyn A.C.; Ratcliffe, Liz; Holden, Elisabeth; Osman, Husam
title: Details of SARS-CoV-2 reinfections at a major UK tertiary centre
date: 2021-03-17
journal: J Infect
DOI: 10.1016/j.jinf.2021.03.004
sha: 7198e1f9a09b8b03ec9519130927fe8c34d70020
doc_id: 1033610
cord_uid: ruflp8ts

nan

examine this.  We observed reinfections in our patients, whole genome sequencing implied variants not previously identified in wave 1 were responsible for these recent infections.

 Further studies are required to define the true impact of reinfections.  Real time whole genome sequencing will be useful to rapidly identify new variants within the hospital setting to facilitate appropriate management of patients.

Although infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been demonstrated to generate a detectable immune response, the susceptibility of previously infected individuals to reinfection is poorly understood. 1 Hanrath et al., (2020) suggested prior SARS-CoV-2 infection in healthcare workers is associated with protection against symptomatic reinfection for up to 6 months. 2 However, in studies of immunity to other coronaviruses, loss of immunity to infection occurs within 1-3 years. 3 Reports of SARS-CoV-2 reinfection events have been published from Brazil, Hong Kong, the Netherlands and Belgium. 1, 4 Here, we discuss SARS-CoV-2 reinfections of patients at University Hospitals Birmingham (UHB) NHS Foundation Trust, using whole genome sequencing to identify responsible variants. summer 2020. 7 The first sequences in England associated with this lineage were identified on 18th July, when quarantine-free travel between the UK and Spain was allowed (10 -26th July 2020). 7 B.1.1.7, the so called Kent variant, was first identified in the UK on 20 th September 2020. 8 Using these data, we deduce that our patients have been re-infected with new COVID-19 variants, as neither was circulating in the UK when the patients first tested positive.

Only the three cases mentioned had laboratory results suggesting reinfection. The other 33 patients either had samples missing from prior infections or the second sample did not sequence. Sequencing often fails when the Ct value is too high or the 6 RLU is too low. 9-10 Further work is warranted to explore this. Another important point is that all these reinfections were in patients who do not meet the PHE criteria for severe immunosuppression which is known to increase the risk of infection. 5 Although our data suggest reinfections occur, it is important to note we have been unable to sequence two paired samples from the same patient. Another point to note is we have not re-confirmed these sequence results.

Exiting the second UK COVID-19 wave, we must recognise the possibility of reinfection and the implications for managing previous positive patients within hospitals. Real time whole genome sequencing will prove useful to rapidly identify new variants and reinfections, facilitating appropriate patient management.

Genomic evidence for reinfection with SARS-CoV-2: a case study

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

The time course of the immune response to experimental coronavirus infection of man

despite high seroprevalence

exposed-healthcare-workers-and-patients-in-hospital-settings/covid-19-management-of-exposed-healthcare-workers-and-patients-in-hospital-settings#section6

A dynamic nomenclature proposal for SARS-CoV-2 to assist genomic epidemiology

Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. medRxiv

COVID-19 Genomics UK Consortium (COG UK)

Understanding cycle threshold (ct) in SARS-CoV-2 RT-PCR. A guide for health protection teams

Analytical and Clinical Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection

We would like to thank the Institute of Microbiology and Infection at the University of Birmingham for undertaking whole genome sequencing on patient SARS-CoV-2 variants detailed in this letter.

All authors have contributed to the manuscript.

None